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The adenomatous polyposis coli (APC) tumor
suppressor protein is inactivated by mutations in the
majority of colorectal cancers. A recent study has
revealed that alterations in the APC signaling pathway
can result in the transcriptional activation of the 
c-MYC gene. 
Addresses: *Division of Molecular Medicine and Genetics,
Departments of Internal Medicine, Human Genetics, and Pathology,
University of Michigan Cancer Center, Ann Arbor, Michigan 48109-
0638, USA. †Division of Hematology, Departments of Medicine and
Oncology, Program in Molecular Medicine, Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA.
E-mail: fearon@umich.edu
Current Biology 1999, 9:R62–R065
http://biomednet.com/elecref/09609822009R0062
© Elsevier Science Ltd ISSN 0960-9822
A widely accepted view is that cancers arise through a
multistep process in which repeated cycles of somatic
mutation and clonal selection produce variant progeny
with highly aggressive growth properties. The genes
affected by mutations in cancer are often divided into two
classes: genes that have gain-of-function (activating)
mutations in cancer are known as oncogenes; and genes
for which both alleles have loss-of-function (inactivating)
mutations in cancer are known as tumor suppressor genes.
Considerable efforts are being expended to define the
range of mutations associated with cancer and to charac-
terize the means by which the mutations, either individu-
ally or collectively, subvert normal growth and cause the
insidious and destructive properties of cancer. 
Now that more than 50 different oncogenes and more than
20 different tumor suppressor genes have been identified,
it has become increasingly apparent that cancer-associated
mutations target conserved signaling pathways. For
instance, the function of the retinoblastoma (pRb) tumor
suppressor protein is regulated by cyclin D1, cyclin-
dependent kinase 4 (Cdk4) and the p16 tumor suppressor
protein (which inhibits Cdk4 activity). Virtually all cancers
have inactivating mutations in the pRb or p16 tumor sup-
pressor genes or activating mutations (for example, gene
amplification) affecting cyclin D1 or Cdk4 [1]. 
Although recurrent clonal mutations have been ascribed a
critical and causal role in cancer development, gene
expression changes in cancer cells themselves have been
viewed more suspiciously. In the absence of a genetic
lesion that accounts for a change in gene expression, it is
not clear whether the altered expression of a particular
gene is a cause or effect of the cancer phenotype, even for
those genes that are known to function as oncogenes or
tumor suppressor genes when mutated. If, however, an
alteration in gene expression can be definitively linked to
a specific mutation in a pathway involving an oncogene or
a tumor suppressor gene, then the argument that the
altered expression has a causal role in cancer development
becomes more compelling.
Bearing these points in mind, one can readily appreciate
the interest stimulated by the recent work from He et al.
[2] describing a relationship between the adenomatous
polyposis coli (APC) tumor suppressor gene pathway and
c-MYC. The c-MYC gene is affected by chromosomal
rearrangements and gene amplifications in certain cancers,
but is perhaps most frequently mutated in Burkitt’s lym-
phoma and small cell lung carcinoma [3]. In most common
types of cancer, however, including colorectal cancer,
c-MYC gene rearrangements and amplifications are rare or
absent. Although earlier studies documented that c-MYC
expression was increased in most colorectal cancers [4],
the basis for altered c-MYC expression in colorectal cancer
and the biological significance of this altered expression
has remained enigmatic. He et al. [2] now provide strong
evidence that increased c-MYC expression in colorectal
cancer is likely to be a direct consequence of mutations
affecting the APC tumor suppressor pathway.
Before considering the findings of He et al. [2] further, it
is useful to review prior insights into APC function.
Germ-line, inactivating mutations in one APC allele are
responsible for familial adenomatous polyposis, and
somatic APC mutations are seen in roughly 70% of col-
orectal adenomas and carcinomas but are rare in other
cancers [5]. APC encodes a large protein of about
300 kDa, and some data suggest that APC might regulate
cell growth in the colonic crypt via effects on shedding
and apoptosis as cells reach the top of the crypt [5]. Con-
sistent with this view, inactivation of APC leads to
marked cellular atypia and disordered growth — termed
dysplasia — in colonic epithelial cells (Figure 1), and
restoration of APC protein expression in colorectal cancer
cells that lack endogenous APC promotes apoptosis [6].
As well as binding to microtubules, the APC protein
binds to various proteins, including β-catenin, γ-catenin,
glycogen synthase kinase 3β (GSK3β), the microtubule-
binding protein EB1, and the cell polarity protein hDLG
[5]. The significance of any of these interactions was not
evident until recently, however, when data established
that a critical function of APC is the regulation of 
β-catenin protein stability.
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The β-catenin protein was initially identified because of
its role in linking the cytoplasmic domain of the cell-adhe-
sion protein E-cadherin to the cortical actin cytoskeleton
[7]. In addition to its role in E-cadherin-mediated cell–cell
adhesion, β-catenin also functions in the Wnt/Wingless
signaling pathway, which is involved in modulating cell
fate, proliferation and behavior during development [7]
(Figure 2). In brief, binding of Wnt to the Frizzled trans-
membrane receptor is believed to activate the Disheveled
protein, which, in turn, inhibits the function of GSK3β.
When bound to APC and axin, GSK3β appears to phos-
phorylate specific serine and threonine residues in the
amino terminus of β-catenin. Phosphorylated but not
unphosphorylated β-catenin is rapidly degraded by the
ubiquitin–proteasome pathway. Wnt activation therefore
promotes the accumulation of unphosphorylated β-catenin
in the cell. Following its accumulation, β-catenin translo-
cates to the nucleus where it binds to the T-cell factor
(Tcf) or lymphoid enhancer factor (Lef) transcription
factors and acts as a transcriptional co-activator, leading to
increased expression of Tcf/Lef-regulated target genes.
Although inactivating mutations in APC are present in the
majority of colorectal cancers, mutations of the amino-ter-
minal presumptive GSK3β phosphorylation sites in
β-catenin have also been found in a minority of colorectal
cancers [8]. In both of these cases — that is, whether APC
is inactivated or β-catenin is non-phosphorylatable —
β-catenin is no longer appropriately regulated (Figure 2).
The protein accumulates in the cell, binds to Tcf/Lef
transcription factors, such as Tcf-4, and activates gene
expression. Therefore, one of the major outstanding issues
with respect to the APC pathway is the identity of the
Tcf-regulated genes that are activated as a result of muta-
tions in APC or β-catenin.
He et al. [2] sought to identify Tcf-regulated genes using a
colorectal cancer cell line in which the endogenous APC
was inactive and an exogenous APC gene could be rapidly
induced. To monitor changes in gene expression following
induction of APC, the serial analysis of gene expression
(SAGE) method was used. In brief, the SAGE technique
is a sequence-based approach that allows an unbiased
assessment of changes in RNA transcript abundance
between different RNA populations. Among the changes
observed, He et al. found that c-MYC expression was
strongly suppressed by APC induction. Further investiga-
tion revealed that the critical elements in the c-MYC pro-
moter that were responsible for APC-mediated
suppression included Tcf-binding sites. Wild-type APC
suppressed the activity of heterologous reporter genes
whose expression was driven by the Tcf regulatory ele-
ments from the c-MYC promoter. Furthermore, expression
of the mutated form of β-catenin led to high levels of acti-
vation of reporter gene expression from these constructs.
The studies of He et al. [2] thus provide strong evidence
that the APC protein may regulate c-MYC expression
through its effects on β-catenin and Tcf-4. Intriguingly, a
role for APC in the regulation of c-MYC gene expression
was first suggested a number of years ago on the basis of
results from two independent lines of investigation. The
first study revealed that increased c-MYC expression was
associated with loss of the chromosome 5q region where
the APC gene resides [9]. The second study observed that
introduction of a normal copy of chromosome 5q into col-
orectal cancer cells suppressed c-MYC expression [10].
What then is the contribution of c-MYC overexpression to
the phenotype of colorectal cancer cells? Since the identi-
fication of c-MYC as a cellular homologue of the retroviral
v-myc oncogene 20 years ago, significant insights into its
function have been gained. The primary product of the
c-MYC gene is a 64 kDa polypeptide that functions as a
transcription factor when heterodimerized with the Max
protein [3]. The regulation of c-Myc target genes is
complex, because other proteins, such as the Mad pro-
teins, compete with c-Myc for binding to Max. In contrast
to the action of Myc–Max heterodimers, Mad–Max het-
erodimers repress transcription of target genes. 
Despite this complexity, many intriguing candidate target
genes of c-Myc have been identified, including those
encoding cell-cycle regulators, such as cdc25A, cyclin A,
Figure 1
Transverse section of a microscopic adenoma from a patient with
familial adenomatous polyposis. Roughly five adenomatous glands are
seen at the top of the figure (arrow), above a collection of normal
colonic glands. The adenomatous glands can be readily distinguished
from the normal glands, because they manifest dysplastic changes.
Characteristic features of dysplastic epithelium include increased
cellularity and abnormal cellular morphology, with hyperchromatic and
spindle-shaped nuclei, nuclear stratification, and loss of nuclear
polarity. The patient from which this sample was taken carries one
mutant and one normal (wild-type) APC allele in each cell of his body.
Inactivation of the remaining wild-type APC allele is believed to be
critical in initiating growth of the dysplastic (adenomatous) glands.
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and cyclin E, as well as proteins associated with DNA
metabolism, such as carbamoyl phosphate synthase,
ornithine decarboxylase, dihydrofolate reductase, thymi-
dine kinase, and the reverse transcriptase component of
telomerase [3]. Other potential c-Myc target genes include
several that encode proteins involved in cellular metabo-
lism, such as the translational regulatory factors eIF-2α
and eIF-4E, the amino acid transporter ECA39, and
lactate dehydrogenase A which participates in anaerobic
glycolysis [3]. Overall, the data imply that increased
expression of the c-Myc protein in colorectal cancer may
directly disrupt cell-cycle control and promote entry into
the S phase of the cell cycle. As He et al. [2] noted, c-MYC
activation appears to have similar effects on cell-cycle
control to those caused by mutations in the pRb–p16
pathway [11], and mutations in the pRb–p16 pathway are
extremely infrequent in colorectal cancer [1]. Because of
its ability to activate genes with important roles in cell
metabolism and energy balance, c-MYC may also facilitate
cell proliferation in conditions that might otherwise
inhibit growth or promote death by apoptosis.
In summary, we now have intriguing insights into the
basis for increased c-MYC expression in colorectal cancer,
and c-MYC’s role is no longer simply one of guilt by associ-
ation. Further studies will be required to determine which
c-Myc target genes are activated in colorectal cancer,
although some potential candidates, such as
prothymosin α, have previously been found to be overex-
pressed in colorectal cancers [12]. Moreover, c-MYC is
likely to be only one of a number of genes activated as a
result of Tcf deregulation. Based on the many histopatho-
logical changes seen in early stage colonic lesions follow-
ing APC inactivation (Figure 1), it seems reasonable to
predict that other genes with roles in cell–cell interaction
and cell proliferation will be identified as critical targets of
the APC–β-catenin–Tcf-4 pathway. An optimistic view is
that focused and well-controlled studies using the power-
ful new technologies for monitoring gene expression
changes will provide us with further insights into onco-
gene and tumor suppressor gene networks as well as into
the biological bases for the development of colorectal and
other cancers.
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A model indicating the function of the APC, axin and GSK3β proteins
in the regulation of β-catenin in normal cells, and the consequence of
APC or β-catenin defects in cancer cells. Much of the abundant
cellular β-catenin protein is often bound to the cytoplasmic domain of
the E-cadherin cell-adhesion protein. (a) In normal cells, GSK3β,
APC and axin promote degradation of free cytosolic β-catenin (β-cat),
probably as a result of phosphorylation of the amino-terminal
sequences of β-catenin by GSK3β. The degradation of β-catenin and
the activity of GSK3β are inhibited by activation of the Wingless/Wnt
pathway, as a result of the action of the Frizzled receptor and the
Disheveled (Dsh) signaling protein. (b) Mutation of APC in colorectal
and other cancer cells results in accumulation of β-catenin, binding of
β-catenin to Tcf-4, and transcriptional activation of Tcf-4 target
genes, such as c-MYC. (c) Point mutations and small deletions in β-
catenin in cancer cells inhibit its phosphorylation and degradation by
GSK3β and APC, with resultant activation of c-MYC and other Tcf-4
target genes.
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If you found this dispatch interesting, you might also want
to read the February 1999 issue of
Current Opinion in
Genetics &Development
which includes the following reviews, edited
by Allan Balmain and Nicholas Dyson, on
Oncogenes and cell proliferation:
Ras caught in another affair: the exchange factors 
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Rob MF Wolthuis and Johannes L Bos
The oncogenic activation of b-catenin
Paul Polakis
The INK4A/ARF locus and its two gene products
Norman E Sharpless and Ronald A DePinho
pRb and E2f-1 in mouse development and
tumorigenesis
Kay Macleod
Histone acetylases and deacetylases in 
cell proliferation
Tony Kouzarides
Target of rapamycin (TOR): balancing the opposing
forces of protein synthesis and degradation
Patrick B Dennis, Stefano Fumagalli and George Thomas
Ap-1 transcription factors in yeast
W Mark Toone and Nic Jones
The regulation of replication origin activation
Anne D Donaldson and J Julian Blow
The spindle checkpoint
Angelika Amon
Coordination of cell growth with cell division
Michael Polymenis and Emmett V Schmidt
Establishing links between developmental signaling
pathways and cell-cycle regulation in Drosophila
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Eukaryotic DNA mismatch repair
Richard D Kolodner and Gerald T Marsischky
Telomere maintenance mechanisms and 
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The full text of Current Opinion in Genetics &
Development is in the BioMedNet library at
http://BioMedNet.com/cbiology/gen
